Search results for " Fatty liver"

showing 10 items of 338 documents

The cheating liver: imaging of focal steatosis and fatty sparing

2016

ABSTRACT: Focal steatosis and fatty sparing are a frequent finding in liver imaging, and can mimic solid lesions. Liver regional variations in the degree of fat accumulation can be related to vascular anomalies, metabolic disorders, use of certain drugs or coexistence of hepatic masses. CT and MRI are the modalities of choice for the noninvasive diagnosis of hepatic steatosis. Knowledge of CT and MRI appearance of focal steatosis and fatty sparing is crucial for an accurate diagnosis, and to rule-out other pathologic processes. This paper will review the CT and MRI techniques for the diagnosis of hepatic steatosis and the CT and MRI features of common and uncommon causes of focal steatosis …

AdultMalemedicine.medical_specialtyPathologyPrognosiComputed Tomography AngiographyAdipose tissuePredictive Value of Testliver030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFat accumulationPredictive Value of TestsRisk FactorsNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineHumansFocal steatosiLiver imagingComputed tomography angiographyAgedintegumentary systemmedicine.diagnostic_testHepatologybusiness.industryRisk FactorFatty liverGastroenterologyMagnetic resonance imagingfatty sparingHepatologyMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingAdipose Tissue030220 oncology & carcinogenesisFemaleRadiologySteatosisbusinessCTMRIFatty Liver AlcoholicHuman
researchProduct

Gut-adipose tissue axis in hepatic fat accumulation in humans

2014

Recent evidence suggests that in animals gut microbiota composition (GMC) affects the onset and progression of hepatic fat accumulation. The aim of this study was to investigate in humans whether subjects with high hepatic fat content (HHFC) differ in their GMC from those with low hepatic fat content (LHFC), and whether these differences are associated with body composition, biomarkers and abdominal adipose tissue inflammation.Hepatic fat content (HFC) was measured using proton magnetic resonance spectroscopy ((1)H MRS). Fecal GMC was profiled by 16S rRNA fluorescence in situ hybridization and flow cytometry. Adipose tissue gene expression was analyzed using Affymetrix microarrays and quant…

AdultMalemedicine.medical_specialtyPathologyeducationGene ExpressionAdipose tissueFaecalibacterium prausnitziiInflammationGut florata3111Insulin resistanceNon-alcoholic Fatty Liver DiseaseInternal medicineGene expressionmedicineHumansTriglyceridesInflammationHepatologybiologymedicine.diagnostic_testMicrobiotata1183ta1182ta3141Middle Agedta3121biology.organism_classificationmedicine.diseaseCross-Sectional StudiesEndocrinologyReal-time polymerase chain reactionAdipose TissueLiverBody CompositionFemaleInsulin Resistancemedicine.symptomDigestive SystemFluorescence in situ hybridizationJournal of Hepatology
researchProduct

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program

2019

BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback. RESULTS Forty-four patients entered the study and 41 completed the assigned training goal (93.2%). In the completer population, 8 weeks of individualised exercise increased …

AdultMalemedicine.medical_specialtyPopulationGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansPharmacology (medical)030212 general & internal medicineYoung adultExercise physiologyPrecision MedicineeducationExerciseLife Styleeducation.field_of_studyInternetHepatologybusiness.industryFatty liverGastroenterologyMiddle Agedmedicine.disease3. Good healthExercise TherapyQuality of LifeElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisbusinessHepatic fibrosisTransient elastographyBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.

2014

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiometabolic risk. Although dyslipidemia represents a key factor in this disease, its impact on serum levels of distinct lipoprotein subfractions is largely unknown.OBJECTIVE: To assess the full low-density lipoprotein (LDL) and high-density lipoprotein (I-EDL) profiles in patients with NAFLD.METHODS: Seven LDL and 10 HDL subfractions were assessed by gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA) in men with biopsy proven NAFLD (simple steatosis [n = 17, age, 34 7 years] and nonalcoholic steatohepatitis [NASH; n = 24, age, 32 +/- 6 years]). Exclusion criteria included robust alcohol consump…

AdultMalemedicine.medical_specialtySimple steatosiEndocrinology Diabetes and MetabolismBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinInsulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineInternal MedicineNutrition and DieteticNonalcoholic fatty liver diseaseHumansAspartate AminotransferasesLipoproteinNutrition and Dieteticsbiologybusiness.industryRisk FactorMedicine (all)Fatty livernutritional and metabolic diseasesAspartate AminotransferaseAlanine TransaminaseLipidMiddle Agedmedicine.diseaseAtherosclerosisFatty LiverLipoproteins LDLEndocrinologyAlanine transaminasechemistryAtherosclerosibiology.proteinFemaleNonalcoholic steatohepatitibusinessCardiology and Cardiovascular MedicineLipoproteins HDLBody mass indexDyslipidemiaLipoproteinHumanJournal of clinical lipidology
researchProduct

Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population

2020

BACKGROUND AND AIMS Non-alcoholic fatty liver (NAFLD) is a major cause of liver disease worldwide leading also to a higher risk of cardiovascular events. We aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk in a general population. METHODS Five hundred and forty-two subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study were recruited. Steatosis (controlled attenuation parameter > 288 dB/m) and severe fibrosis (low risk, liver stiffness measurement [LSM] < 7.9 KPa with M probe and < 5.7 KPa with XL probe; intermediate risk, LSM 7.9-9.5 KPa with M probe and 5.7-9.2 KPa with XL probe; high risk, LSM ≥ 9.6 KPa with…

Adultcardiovascular riskmedicine.medical_specialtyPopulationGastroenterologyAsymptomatic03 medical and health sciencesLiver disease0302 clinical medicineatherosclerosiNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineNAFLDmedicineHumansSettore MED/49 - Scienze Tecniche Dietetiche Applicateeducationeducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryFatty liverConfoundingGastroenterologyOdds ratiomedicine.diseasecarotidCardiovascular DiseasesHeart Disease Risk Factors030220 oncology & carcinogenesisABCD studyfatty liver disease030211 gastroenterology & hepatologySteatosismedicine.symptombusiness
researchProduct

Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling

2014

The generation of excessive amounts of reactive oxygen species (ROS) leads to cellular oxidative stress that underlies a variety of forms of hepatocyte injury and death including that from alcohol. Although ROS can induce cell damage through direct effects on cellular macromolecules, the injurious effects of ROS are mediated largely through changes in signal transduction pathways such as the mitogen-activated protein kinase c-Jun N-terminal kinase (JNK). In response to alcohol, hepatocytes have increased levels of the enzyme cytochrome P450 2E1 (CYP2E1) which generates an oxidant stress that promotes the development of alcoholic steatosis and liver injury. These effects are mediated in larg…

Alcoholic liver diseaseClinical BiochemistryReview ArticleMitogen-activated protein kinase kinasemedicine.disease_causeBiochemistryCytochrome P450 2E10302 clinical medicineMolecular Targeted TherapyMitogen-activated protein kinaseslcsh:QH301-705.5c-Jun N-terminal kinasechemistry.chemical_classificationTNF tumor necrosis factorlcsh:R5-9200303 health sciencesCell DeathCYP2E1 cytochrome P450 2E1Cytochrome P-450 CYP2E13. Good healthCell biologyPKD protein kinase DLiverJNK c-Jun N-terminal kinaseSab SH3 homology associated BTK binding protein030211 gastroenterology & hepatologySignal transductionlcsh:Medicine (General)MAP Kinase Signaling SystemAPAP acetaminophenMKK MAPK kinaseBiology03 medical and health sciencesROS reactive oxygen speciesPKC protein kinase CmedicineAnimalsHumansMAPKKK MAPK kinase kinaseProtein kinase ACell damage030304 developmental biologyReactive oxygen speciesMAP kinase kinase kinaseOrganic ChemistryJNK Mitogen-Activated Protein KinasesAlcoholic liver diseasemedicine.diseaseERK1/2 extracellular signal-regulated kinase 1/2Fatty Liverlcsh:Biology (General)chemistryOxidative stressNAFLD nonalcoholic fatty liver diseaseReactive Oxygen SpeciesMAPK mitogen-activated protein kinaseOxidative stressRedox Biology
researchProduct

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of…

2019

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children &lt;3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body ma…

Alcoholic liver diseasemedicine.medical_specialtyobesitybifidobacteriumGastroenterology03 medical and health sciences0302 clinical medicineInsulin resistanceDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumans030212 general & internal medicine1506BifidobacteriumRandomized Controlled Trials as Topic2. Zero hunger[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismNutrition and Metabolismbiologydiabetesbusiness.industryProbioticsResearchFatty livernon-alcoholic fatty liver diseaseGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseasebiology.organism_classificationPolycystic ovaryObesity3. Good healthlactobacillus[SDV.AEN] Life Sciences [q-bio]/Food and NutritionTreatment Outcome[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieDietary Supplements[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie1714businessBody mass index[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryBMJ open
researchProduct

The role of morbid obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2016

Background Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and methods Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 su…

Blood GlucoseMalePhysiologyBiopsylcsh:MedicineType 2 diabetesPathology and Laboratory MedicineBiochemistryGastroenterologyLiver diseaseEndocrinology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceImmune ResponseMultidisciplinarymedicine.diagnostic_testLiver DiseasesFatty liverMiddle AgedObesity MorbidPhysiological ParametersLiver biopsyCarbohydrate MetabolismFemale030211 gastroenterology & hepatologyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersImmunologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyHelicobacter Infections03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansObesityInflammationHelicobacter pyloriEndocrine Physiologybusiness.industryBody Weightlcsh:RBiology and Life Sciencesmedicine.diseaseImpaired fasting glucoseMorbid ObesityFatty LiverCross-Sectional StudiesMetabolismEndocrinologyDiabetes Mellitus Type 2Metabolic Disorderslcsh:QInsulin ResistanceSteatohepatitisbusiness
researchProduct

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

2021

International audience; Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver …

Blood PlateletsLiver CirrhosisNoninvasive Diagnosismedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]PopulationEsophageal and Gastric VaricesChronic liver diseaseSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseEsophageal varicesInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationBaveno VI CriteriaRetrospective Studieseducation.field_of_studyHepatologybusiness.industryGastroenterologyRetrospective cohort studyPortal Hypertensionmedicine.disease3. Good healthMELDCirrhosis030220 oncology & carcinogenesisElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessBaveno VI Criteria Blood Platelets Cirrhosis Elasticity Imaging Techniques End Stage Liver Disease Esophageal and Gastric Varices Humans Liver Cirrhosis MELD Noninvasive Diagnosis Portal Hypertension Retrospective Studies Severity of Illness Index
researchProduct